Investigating and targeting IGF1 in osteoarthritis: from mechanisms to disease modification.
Description: Osteoarthritis (OA), the most common joint disease, is a major cause of disability and pain, yet disease-modifying therapies remain unavailable. My PhD research identified insulin-like growth factor 1 (IGF1) as critical mediator of the detrimental effects triggered by Wnt signaling in the joint. This project seeks (1) to investigate the mechanisms via which IGF1 triggers joint damage, (2) to develop IGF1-targeted preclinical therapies, and (3) to explore the role of IGF1 in aging-related OA. First, we will study IGF1’s receptor binding and intracellular signaling molecules. Our preliminary data indicate that the main IGF1 receptor (IGF1R) has limited impact in our models, prompting us to explore alternative IGF1 receptors and roles of IGF1 isoforms and its processed peptides. Secondly, we will focus on pharmacological strategies to block IGF1. Preliminary data show that IGF binding protein 4 (IGFBP4) can attenuate IGF1 harmful effects in chondrocytes. We will evaluate IGFBP4’s therapeutic potential in cartilage explants and a posttraumatic OA mouse model. Finally, we will study the role of IGF1 in aging-induced OA, by examining age-related changes in IGF1 and analyzing the impact of aging in cartilage-specific Igf1 KO mice. This is relevant given the prevalence of OA among older adults, whose disease mechanisms may differ from those of younger patients with posttraumatic OA. My study will bridge crucial knowledge gaps paving the way for innovative strategies to halt OA
Funder: Vlaamse regering
Funding type: fellowship
Funder scheme: BOF - postdoctoral mandates
Start date: 2025-10-01
End date: 2026-09-30
Investigators: Ana Escribano Núñez (lead), Rik Lories (co-lead)
Institutions: KU Leuven, KULeuven
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Funded outputs count: 0
Funder award ID: PDMT1/25/005
OpenAlex ID: G552599836
